Talphera (TLPH) Current Deferred Revenue (2013 - 2022)
Talphera (TLPH) posted Current Deferred Revenue of $1.2 million for Q4 2022, down 3.6% on a QoQ basis from $1.2 million in Q3 2022, and down 6.95% year-over-year from $1.2 million in Q4 2021.
Analysis
Talphera (TLPH) Current Deferred Revenue (2013 - 2022) Analysis & Trends
Talphera has reported Current Deferred Revenue for 10 years, with the latest figure at $1.2 million in Q4 2022.
- On a quarterly basis, Current Deferred Revenue fell 6.95% year-over-year to $1.2 million in Q4 2022; TTM through Dec 2022 was $1.2 million, a 6.95% decrease from a year earlier, with the FY2022 full-year figure at $1.2 million, down 6.95% from the prior year.
- Current Deferred Revenue was $1.2 million for Q4 2022 at Talphera, down from $1.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $3.5 million in Q1 2019, with the low at $49000.0 in Q4 2020.
- Average Current Deferred Revenue over 5 years is $1.6 million, with a median of $1.2 million recorded in 2021.
- The sharpest annual moves came in 2020 and 2021: Current Deferred Revenue tumbled 98.49% in 2020, then jumped 2424.49% in 2021.
- Over 5 years, Current Deferred Revenue stood at $3.5 million in 2018, then declined by 6.32% to $3.2 million in 2019, then sank by 98.49% to $49000.0 in 2020, then surged by 2424.49% to $1.2 million in 2021, then retreated by 6.95% to $1.2 million in 2022.
- The last three Current Deferred Revenue figures came in at $1.2 million (Q4 2022), $1.2 million (Q3 2022), and $1.2 million (Q2 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.24 Mn |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Dec 31, 2020 | 49,000.00 |
| Sep 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 343,000.00 |
| Mar 31, 2020 | 3.17 Mn |
| Dec 31, 2019 | 3.24 Mn |
| Sep 30, 2019 | 3.23 Mn |
| Jun 30, 2019 | 3.31 Mn |
| Mar 31, 2019 | 3.51 Mn |
| Dec 31, 2018 | 3.46 Mn |
| Sep 30, 2018 | 326,000.00 |
| Jun 30, 2018 | 338,000.00 |
| Mar 31, 2018 | 350,000.00 |
| Dec 31, 2017 | 362,000.00 |
| Sep 30, 2017 | 362,000.00 |